Biological and Biosimilars Drug Market in Poland 2013

Publisher Name :
Date: 31-Aug-2013
No. of pages: 120

Examine the future of biologics in the Polish pharma market.

Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015.

In Poland, as in many parts of the world, a growing number of patients are being treated using biological or biosimilar drugs. The list of illnesses for which these drugs are prescribed includes psoriasis, Crohn’s disease, colitis, psoriatic and rheumatoid arthritis, ankylosing spondylitis and others. Consequently, the market has expanded recently to encompass new drugs and therapies designed to treat a growing variety of conditions and illnesses.

Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a new PMR report designed to evaluate current market conditions and investigate the possibilities for growth and expansion in the coming years. From market size to research and development efforts of leading companies, this publication offers expert analysis of this market.

This document analyses the epidemiology fueling the growth of biologics in Poland, revealing the number of patients receiving these drugs. It analyses the reasons behind expansion and the potential obstacles that exist or will appear by 2015.

The competitive atmosphere of this segment of Poland’s pharmaceuticals market is carefully evaluated using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions to their product lines and plans to engage in new research and development activities. Recent entries into the Polish biologics market are examined along with the likelihood of M&A and consolidation activity in the next two years.

The expiration of various patents for biologic drugs is a timely market topic, and this publication highlights the businesses ready to capitalise on new developments. It reviews the mechanics of the market, offering explanation of the registration and refund procedures that apply to biologics in Poland and covering recent and upcoming regulatory changes and their likely impact on businesses supplying this market.

Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a long-awaited business information tool that will aid companies involved in the manufacturing and distribution of these drugs within the Polish market and especially those which want to enter this young market. Related companies engaged in ingredient manufacturing and drug research will also find this report vital to new drug development, keeping up with legal requirements for business operation in this segment and preparing corporate reports and forecasts for internal use. Users of this publication come from pharmaceutical companies, consulting and research services providers and government agencies, financial institutions and chambers of commerce.

Biological and Biosimilars Drug Market in Poland 2013

Table Of Contents

I. Methodology 9

II. Executive summary 15

III. Market overview 19

IV. Results of the survey conducted among 35 companies operating on the market of biologicals and biosimilars in Poland 37

V. Biologicals in treatment of selected diseases in Poland 49

VI. Profiles of selected companies operating in the sector in Poland 97

VII. List of graphs 113

VIII. List of tables 117

IX. About PMR 119

  • Global Dental Implants Market Driven by Demand in Cosmetic Dentistry
    The global market for dental implants has been witnessing steady growth in the last couple of years due to increased demand for cosmetic dentistry and rise in incidences of dental disorders. People’s awareness about aesthetic dentistry procedures has increased in recent years, which is also fueling the growth of the dental implant market. With economic [...]
  • Air Traffic Management and Control Market Driven by Technological Advancement
    The global market for air traffic management and control has grown steadily in the last couple of years with increase in air traffic volume and congestion. Air Traffic Control (ATC) consists of an elaborate system of ground stations, radar arrays and professional air traffic controllers. With increase in air travel for business and leisure, as [...]
  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Biosimilars – Biosimilars on the cusp of a new era
    Published: 31-Jul-2014        Price: US $2995 Onwards        Pages: 58
    The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies the FDA and EMA. Moreover, there are some concerns around biosimilar use, for example w......
  • PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market
    Published: 30-Jun-2014        Price: US $2995 Onwards        Pages: 173
    GlobalData's report, "PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market", provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements in various markets, recent deals activity and trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as India providi......
  • Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan – It’s Time to Welcome Antibody Biosimilars of Foreign Origins Soon
    Published: 21-Feb-2014        Price: US $2500 Onwards        Pages: 31
    With three products and eight players already in market – Japan biosimilar market will enter new phase of biosimilars with first ‘mab’ approval expected in 2014.  This approval (Remicade- FY03/13A sales ¥73.5, infiximab from Nippon Kayaku by YE 14) will be marked as a milestone development because – 1.) it will open antibody biosimilar market in Japan, and 2.) the approval will be based largely from overseas data. ~ ¥200b worth of biologic products is going off patent by 2015 and t......
  • Global Biosimilars Market 2014-2018
    Published: 14-Feb-2014        Price: US $3000 Onwards        Pages: 106
    TechNavio's analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. TechNavio's report, the Global Biosimilars Market 2014-2018, has been pre......
  • Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018
    Published: 18-Nov-2013        Price: US $4650 Onwards        Pages: 320
    The global is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down ......
  • Therapy Class Overview : Rituximab Biosimilar
    Published: 7-Oct-2013        Price: US $2000 Onwards        
    Approval of Inflectra/Remsima,  the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year.  This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc......
  • The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition
    Published: 22-Sep-2013        Price: US $2995 Onwards        Pages: 195
    This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greate......
  • Biosimilar Opportunities in an Evolving Market
    Published: 1-Aug-2013        Price: US $1495 Onwards        Pages: 113
    Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency's Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson's infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs